长春高新：子公司GenSci098注射液境内生产药品注册临床试验申请获得批准

Core Viewpoint - Changchun Gaoxin's subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial application of GenSci098 injection, which shows potential for treating diffuse toxic goiter [1] Group 1 - The clinical trial approval for GenSci098 injection is a significant step towards its clinical development for the target population suffering from diffuse toxic goiter [1]